Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial

Overview

Journal Dermatol Ther (Heidelb)

Date 2022 Jan 13

PMID 35025062

Authors

Diamant Thaci

Bruce Strober

Kenneth B Gordon

Peter Foley

Melinda Gooderham

Akimichi Morita

Kim A Papp

Lluis Puig

M Alan Menter

Matthew J Colombo

Yedid Elbez

Renata M Kisa

June Ye

Andrew A Napoli

Lan Wei

Subhashis Banerjee

Joseph F Merola

Alice B Gottlieb

Affiliations

Soon will be listed here.

Abstract

Introduction: Deucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that demonstrated therapeutic benefit in a Phase 2 clinical trial of adults with moderate to severe plaque psoriasis. This analysis was designed to evaluate the effect of deucravacitinib on additional clinical and quality-of-life (QoL) outcomes and assess the relationship between these outcomes in adults with psoriasis.

Methods: Post-hoc analysis of a 12-week Phase 2 trial was conducted for the three most efficacious dosage groups (3 mg twice daily, 6 mg twice daily, 12 mg once daily) and placebo. Investigator assessments for efficacy included Psoriasis Area and Severity Index (PASI), body surface area (BSA) involvement, and static Physician's Global Assessment; QoL was assessed using the Dermatology Life Quality Index (DLQI). Treatment responses and their associations were evaluated over time.

Results: Deucravacitinib elicited improvement versus placebo as early as Week 4 for most efficacy measures (including changes in absolute PASI and BSA), with efficacy trends observed from Week 2 to Week 12. Improvements in QoL, assessed by achievement of a DLQI overall score of 0/1 (no effect at all on patient's life), followed a pattern similar to deucravacitinib-related clinical outcomes over 12 weeks. Overall, patients with greater improvements in psoriasis-related clinical signs and symptoms also reported greater improvement in QoL. However, complete skin clearance was not required for achieving DLQI 0/1.

Conclusion: Deucravacitinib treatment produced early response and similar trends in improvements across multiple efficacy assessments and QoL in moderate to severe plaque psoriasis. Deucravacitinib has the potential to become a promising new oral therapy for this condition.

Trial Registration: ClinicalTrials.gov identifier; NCT02931838.

Citing Articles

Discovery of GLPG3667, a Selective ATP Competitive Tyrosine Kinase 2 Inhibitor for the Treatment of Autoimmune Diseases.

Mammoliti O, Martina S, Claes P, Coti G, Blanque R, Jagerschmidt C J Med Chem. 2024; 67(11):8545-8568.

PMID: 38805213 PMC: 11181332. DOI: 10.1021/acs.jmedchem.4c00769.

Using Automated Machine Learning to Predict Necessary Upcoming Therapy Changes in Patients With Psoriasis Vulgaris and Psoriatic Arthritis and Uncover New Influences on Disease Progression: Retrospective Study.

Schaffert D, Bibi I, Blauth M, Lull C, von Ahnen J, Gross G JMIR Form Res. 2024; 8:e55855.

PMID: 38738977 PMC: 11240079. DOI: 10.2196/55855.

A paradigm shift in psoriasis treatment: deucravacitinib's significance.

Ishtiaque G, Supti F, Amin R, Emran T Ann Med Surg (Lond). 2023; 85(12):5866-5868.

PMID: 38098574 PMC: 10718337. DOI: 10.1097/MS9.0000000000001484.

JAK Inhibitors in Psoriatic Disease.

Megna M, Potestio L, Ruggiero A, Cacciapuoti S, Maione F, Tasso M Clin Cosmet Investig Dermatol. 2023; 16:3129-3145.

PMID: 37927384 PMC: 10625379. DOI: 10.2147/CCID.S433367.

The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.

Qiu J, Liu J, Liu W, Lin F, Shi N Front Med (Lausanne). 2023; 10:1264667.

PMID: 37841017 PMC: 10570425. DOI: 10.3389/fmed.2023.1264667.

References

Spuls P, Lecluse L, Poulsen M, Bos J, Stern R, Nijsten T . How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol. 2010; 130(4):933-43. DOI: 10.1038/jid.2009.391. View

Feldman S, Krueger G . Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005; 64 Suppl 2:ii65-8. PMC: 1766877. DOI: 10.1136/ard.2004.031237. View

Menter A, Gottlieb A, Feldman S, Van Voorhees A, Leonardi C, Gordon K . Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008; 58(5):826-50. DOI: 10.1016/j.jaad.2008.02.039. View

FREDRIKSSON T, Pettersson U . Severe psoriasis--oral therapy with a new retinoid. Dermatologica. 1978; 157(4):238-44. DOI: 10.1159/000250839. View

Papp K, Gordon K, Thaci D, Morita A, Gooderham M, Foley P . Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. N Engl J Med. 2018; 379(14):1313-1321. DOI: 10.1056/NEJMoa1806382. View

Armstrong A, Siegel M, Bagel J, Boh E, Buell M, Cooper K . From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. J Am Acad Dermatol. 2016; 76(2):290-298. DOI: 10.1016/j.jaad.2016.10.017. View

Finlay A, Khan G . Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994; 19(3):210-6. DOI: 10.1111/j.1365-2230.1994.tb01167.x. View

Katugampola R, Lewis V, Finlay A . The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol. 2007; 156(5):945-50. DOI: 10.1111/j.1365-2133.2007.07817.x. View

Nogueira M, Puig L, Torres T . JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors. Drugs. 2020; 80(4):341-352. DOI: 10.1007/s40265-020-01261-8. View

10.

Walsh J, McFadden M, Woodcock J, Clegg D, Helliwell P, Dommasch E . Product of the Physician Global Assessment and body surface area: a simple static measure of psoriasis severity in a longitudinal cohort. J Am Acad Dermatol. 2013; 69(6):931-7. DOI: 10.1016/j.jaad.2013.07.040. View

11.

Chow C, Simpson M, Luger T, Chubb H, Ellis C . Comparison of three methods for measuring psoriasis severity in clinical studies (Part 1 of 2): change during therapy in Psoriasis Area and Severity Index, Static Physician's Global Assessment and Lattice System Physician's Global Assessment. J Eur Acad Dermatol Venereol. 2015; 29(7):1406-14. DOI: 10.1111/jdv.13132. View

12.

Simpson M, Chow C, Morgenstern H, Luger T, Ellis C . Comparison of three methods for measuring psoriasis severity in clinical studies (Part 2 of 2): use of quality of life to assess construct validity of the Lattice System Physician's Global Assessment, Psoriasis Area and Severity Index and Static.... J Eur Acad Dermatol Venereol. 2015; 29(7):1415-20. DOI: 10.1111/jdv.12861. View

13.

Hongbo Y, Thomas C, Harrison M, Salek M, Finlay A . Translating the science of quality of life into practice: What do dermatology life quality index scores mean?. J Invest Dermatol. 2005; 125(4):659-64. DOI: 10.1111/j.0022-202X.2005.23621.x. View

14.

Gottlieb A, Merola J, Chen R, Levi E, Callis Duffin K . Assessing clinical response and defining minimal disease activity in plaque psoriasis with the Physician Global Assessment and body surface area (PGA × BSA) composite tool: An analysis of apremilast phase 3 ESTEEM data. J Am Acad Dermatol. 2017; 77(6):1178-1180. DOI: 10.1016/j.jaad.2017.06.162. View

15.

Gottlieb A, Germino R, Herrera V, Meng X, Merola J . Exploration of the Product of the 5-Point Investigator's Global Assessment and Body Surface Area (IGA × BSA) as a Practical Minimal Disease Activity Goal in Patients with Moderate-to-Severe Psoriasis. Dermatology. 2019; 235(4):348-354. PMC: 6690410. DOI: 10.1159/000499925. View

16.

Merola J, Amato D, See K, Burge R, Mallinckrodt C, Ojeh C . Evaluation of sPGA × BSA as an Outcome Measure and Treatment Target for Clinical Practice. J Invest Dermatol. 2018; 138(9):1955-1961. DOI: 10.1016/j.jid.2018.01.041. View

17.

Armstrong A, Schupp C, Wu J, Bebo B . Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. PLoS One. 2013; 7(12):e52935. PMC: 3532407. DOI: 10.1371/journal.pone.0052935. View

18.

Armstrong A, Quintero D, Echeverria C, Gu Y, Karunaratne M, Reyes Servin O . Body Region Involvement and Quality of Life in Psoriasis: Analysis of a Randomized Controlled Trial of Adalimumab. Am J Clin Dermatol. 2016; 17(6):691-699. PMC: 5110581. DOI: 10.1007/s40257-016-0229-x. View

19.

Hrehorow E, Salomon J, Matusiak L, Reich A, Szepietowski J . Patients with psoriasis feel stigmatized. Acta Derm Venereol. 2011; 92(1):67-72. DOI: 10.2340/00015555-1193. View

20.

Revicki D, Willian M, Menter A, Saurat J, Harnam N, Kaul M . Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis. Dermatology. 2008; 216(3):260-70. DOI: 10.1159/000113150. View